Stay updated on Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedMelanoma and MedlinePlus Genetics were added as related topics, and publication descriptions were updated with revised wording. These are minor editorial updates to the study page.SummaryDifference0.3%

- Check28 days agoChange DetectedRemoval of the government funding/operating-status notice at the top of the page. The study details and other content are unaffected.SummaryDifference0.4%

- Check35 days agoChange DetectedDeleted topics: Melanoma and MedlinePlus Genetics. This reduces the disease-specific context and related resources available on the page.SummaryDifference0.2%

- Check42 days agoChange DetectedBoth screenshots show the same study page for NCT01866319, with pembrolizumab vs ipilimumab in advanced melanoma and identical trial details. The changes appear to be cosmetic UI/layout adjustments, not alterations to the study design, eligibility criteria, or reported outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check49 days agoChange DetectedMelanoma and MedlinePlus Genetics were added to the related topics section, representing a minor metadata update to the page. Only related topics metadata were updated; no changes to core content, eligibility criteria, endpoints, or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check63 days agoChange Detected- Removed a MedlinePlus Genetics topic on Melanoma; a deletion of a specific disease-related topic with minimal broader impact.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.